Medisse raises $3.5M for new med device biomaterial

Medisse in The Netherlands attracted $3.5 million in new Series B equity funding, money that will come in handy as the company develops its FlexiSurge adhesion barrier. Medisse, first launched in 2009, develops resorbable soft tissue-related implants that are based on a flexible material. Plans call for using the funds to launch a proof of concept clinical trial for FlexiSurge, with a goal of obtaining a CE mark. The latest investment round drew one new investor--IIG--along with previous investors BioGeneration Ventures and Omnes Capital. As part of the deal, the Dutch Ministry of Economic Affairs also issued an innovation credit, the company notes. Item

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.